- Home
- GNLX vs RLMD Comparison
GNLX vs RLMD Comparison
Compare GNLX & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNLX
- RLMD
- Stock Information
- Founded
- GNLX 2001
- RLMD 2004
- Country
- GNLX United States
- RLMD United States
- Employees
- GNLX N/A
- RLMD N/A
- Industry
- GNLX Biotechnology: Pharmaceutical Preparations
- RLMD Biotechnology: Pharmaceutical Preparations
- Sector
- GNLX Health Care
- RLMD Health Care
- Exchange
- GNLX Nasdaq
- RLMD Nasdaq
- Market Cap
- GNLX 103.6M
- RLMD 110.6M
- IPO Year
- GNLX 2023
- RLMD N/A
- Fundamental
- Price
- GNLX $2.27
- RLMD $0.36
- Analyst Decision
- GNLX Strong Buy
- RLMD Hold
- Analyst Count
- GNLX 4
- RLMD 4
- Target Price
- GNLX $18.25
- RLMD $4.25
- AVG Volume (30 Days)
- GNLX 142.7K
- RLMD 2.1M
- Earning Date
- GNLX 11-14-2024
- RLMD 11-07-2024
- Dividend Yield
- GNLX N/A
- RLMD N/A
- EPS Growth
- GNLX N/A
- RLMD N/A
- EPS
- GNLX N/A
- RLMD N/A
- Revenue
- GNLX $8,000.00
- RLMD N/A
- Revenue This Year
- GNLX N/A
- RLMD N/A
- Revenue Next Year
- GNLX N/A
- RLMD N/A
- P/E Ratio
- GNLX N/A
- RLMD N/A
- Revenue Growth
- GNLX N/A
- RLMD N/A
- 52 Week Low
- GNLX $1.60
- RLMD $0.34
- 52 Week High
- GNLX $16.60
- RLMD $7.22
- Technical
- Relative Strength Index (RSI)
- GNLX 38.68
- RLMD 17.00
- Support Level
- GNLX $2.13
- RLMD $0.34
- Resistance Level
- GNLX $2.80
- RLMD $0.40
- Average True Range (ATR)
- GNLX 0.20
- RLMD 0.09
- MACD
- GNLX -0.04
- RLMD -0.02
- Stochastic Oscillator
- GNLX 14.21
- RLMD 0.72
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec) and others.
About RLMD Relmada Therapeutics Inc.
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its lead product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.